Loading
Continuing immunotherapy after it has failed, alongside a targeted pill, added nothing but side effects. The first definitive test of 'IO rechallenge'.
CONTACT-03, trial NCT04338269 sponsored by Roche and Exelixis and published in the Lancet in 2023, was the first definitive test of immunotherapy rechallenge in kidney cancer, and it found that continuing PD-L1 blockade after progression on immunotherapy, alongside cabozantinib, added nothing but side effects. It randomised 522 patients with advanced renal cell carcinoma progressing on or after a PD-1 or PD-L1 inhibitor to atezolizumab plus cabozantinib or cabozantinib alone and found no difference in progression-free or overall survival with more toxicity. OnCo links it to renal cell carcinoma, atezolizumab, cabozantinib, Sumanta K. Pal, Neeraj Agarwal and a caution pairing about PD-1 rechallenge after progression. It changed practice so that rechallenge is no longer recommended, and whether any biomarker-defined subgroup might still benefit is the open question.
Numbers are from the trial as recorded here; see the source links in the table below. This is orientation, not medical advice: ask your team how closely the trial population matches you.
522 enrolled.
| Endpoint | Arm | n | Value | HR (95% CI) | p | Source |
|---|---|---|---|---|---|---|
| Progression-free survivalprimary | Atezolizumab + cabozantinib | 263 | 10.6 months | 1.03 (0.83 to 1.28) | - | link |
| Cabozantinib | 259 | 10.8 months |
Shares Sumanta K. Pal, Exelixis, Cabozantinib, Renal cell carcinoma.
Shares Exelixis, Cabozantinib, Atezolizumab, Immune checkpoint inhibitors.
Shares Sumanta K. Pal, Exelixis, Cabozantinib, Renal cell carcinoma.
Shares Exelixis, Cabozantinib, Atezolizumab, Immune checkpoint inhibitors.
Shares Exelixis, Cabozantinib, Atezolizumab, Immune checkpoint inhibitors.
Shares Exelixis, Cabozantinib, Atezolizumab, Immune checkpoint inhibitors.
Shares Exelixis, Cabozantinib, Immune checkpoint inhibitors.
Shares Exelixis, Cabozantinib.